Tag: Thomas A. Ciulla


Clearside Biomedical Inc (NASDAQ: CLSD) Proclaims Optimistic Security Consequences from Cohort 1 of OASIS Phase 1/2a Clinical Pilot of CLS-AX

Clearside Biomedical Inc (NASDAQ: CLSD), a biopharmaceutical company, proclaimed today optimistic security consequences from Cohort 1 of OASIS, its continuing Phase 1/2a scientific pilot of CLS-AX (axitinib injectable suspension) managed by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD). The main […]